Bruker Corporation (BRKR) recently announced its progress in immunopeptidomics, glycoproteomics and other CCS-enabled 4D-proteomics workflows at the 20th US Human Proteome Organization Congress 2024. The advances include improved machine-learning de novo sequencing (Novor V2.0), a novel high-performance monitoring digital-twin software (TwinScape), the new glyco-PASEF method for high-sensitivity glycopeptide analysis and access to Spectronaut 18 for users of Bruker ProteoScape — a GPU-powered software for r ...